Application of the ACMG/NSGC genetic referral guidelines for hereditary renal cell carcinoma at the University of Miami, from 2014 to 2017.
ACMG/NSGC criteria
genetic referral
genetic testing
hereditary cancer
renal cell carcinoma
Journal
American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
31
05
2021
received:
28
04
2021
accepted:
05
06
2021
pubmed:
22
6
2021
medline:
21
1
2022
entrez:
21
6
2021
Statut:
ppublish
Résumé
Identifying hereditary syndromes among patients with renal cell carcinoma (RCC) is essential for surveillance of affected individuals and their at-risk family members and for treatment optimization. We conducted a chart review to determine the percentage of patients with RCC who were seen at the University of Miami Health System (UHealth), and met the American College of Medical Genetics (ACMG) and the National Society of Genetic Counselors (NSGC) genetic referral criteria at the University of Miami. Subsequently, we determined the percentage of those who went on to receive genetic evaluation. Patients selected by International Classification of Diseases (ICD) 9/10 codes corresponding to kidney cancer who were at least 18 years of age at the time of diagnosis were included in the study. We included a total of 1443 patients in the final analysis, and after exclusion of charts with incorrect ICD codes, insufficient clinical data, unknown pathology, and patients who were not seen. We used chi-square analysis, ANOVA, and t-test. Of 1443 charts reviewed, 65.7% were male and 34.3% were female. 47.7% self-identified as White, 39.2% as Hispanic, 9.1% as Black, and 4.0% as "other." The mean age of RCC diagnosis was 60.0 ± 12.4 years old. In total, 47.0% of patients met ACMG/NSGC referral criteria for genetic evaluation. Of those, only 4.2% had documented genetic assessment. This study showed a low adherence to ACMG/NSGC genetic referral guidelines at our institution and a need for increasing patients' and practitioners' awareness about the significance of genetic assessment for RCC patients and their family members.
Identifiants
pubmed: 34152076
doi: 10.1002/ajmg.a.62402
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3012-3018Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Allasia, M., Soria, F., Battaglia, A., Gazzera, C., Calandri, M., Caprino, M. P., Lucatello, B., Velrti, A., Maccario, M., Pasini, B., Bosio, A., Gontero, P., & Destefanis, P. (2017). Radiofrequency ablation for renal cancer in Von Hippel-Lindau syndrome patients: A prospective cohort analysis. Clinical Genitourinary Cancer, 16(1), 28-34. https://doi.org/10.1016/j.clgc.2017.07.027.
Bashford, M. T., Kohlman, W., Everett, J., Parrott, A., Pollin, T. I., & Practice Guidelines Committee of the National Society of Genetic Counselors and the Professional Practice and Guidelines Committee of the American College of Medical Genetics and Genomics. (2019). Addendum: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: Referral indications for cancer predisposition assessment. Genetics in Medicine, 21(12), 2844.
Benusiglio, P. R., Giraud, S., Deveaux, S., Mejean, A., Correas, J. M., Joly, D., Timsit, M. O., Ferlicot, S., Verkarre, V., Abadie, C., Chauveau, D., Leroux, D., Avril, M. F., Cordier, J. F., Richard, S., & French National Cancer Institute Inherited Predisposition to Kidney Cancer Network. (2014). Renal cell tumour characteristics in patients with the Birt-Hogg-Dube cancer susceptibility syndrome: A retrospective, multicentre study. Orphanet Journal of Rare Diseases, 9, 163.
Binderup, M. L. M. (2018). von Hippel-Lindau disease: Diagnosis and factors influencing disease outcome. Danish Medical Journal, 65(3), B5461.
Carlo, M. I., Mukherjee, S., Mandelker, D., Vijai, J., Kemel, Y., Zhang, L., Knezevic, A., Patil, S., Ceyhan-Birsoy, O., Huang, K. C., Redzematovic, A., Coskey, D. T., Stewart, C., Pradhan, N., Arnold, A. G., Hakimi, A. A., Chen, Y. B., Coleman, J. A., Hyman, D. M., … Offit, K. (2018). Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma. JAMA Oncology, 4(9), 1228-1235.
Dabestani, S., Thorstenson, A., Lindblad, P., Harmenberg, U., Ljungberg, B., & Lundstam, S. (2016). Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: A population-based study. World Journal of Urology, 34(8), 1081-1086.
Hampel, H., Bennett, R. L., Buchanan, A., Pearlman, R., Wiesner, G. L., & Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee. (2015). A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: Referral indications for cancer predisposition assessment. Genetics in Medicine, 17(1), 70-87.
Kallinikas, G., Habib, H., Tsimiliotis, D., Koutsokostas, E., & Bokor, B. (2017). Renal cell cancers: Unveiling the hereditary ones and saving lives-a tailored diagnostic approach. International Urology and Nephrology, 49(9), 1507-1512.
Kne, A., Zierhut, H., Baldinger, S., Swenson, K. K., Mink, P., Veach, P. M., & Tsai, M. L. (2017). Why is cancer genetic counseling underutilized by women identified as at risk for hereditary breast cancer? Patient perceptions of barriers following a referral letter. Journal of Genetic Counseling, 26(4), 697-715.
Kushnir, I., Kirk, L., Mallick, R., Kim, R. H., Graham, G. E., Breau, R. H., Lattouf, J. B., Violette, P. D., Pautler, S. E., Care, M., Kapoor, A., Jewett, M. A. S., Wood, L., Tanguay, S., Heng, D. Y. C., Basappa, N. S., So, A., Pouliot, F., & Reaume, N. M. (2020). Application of hereditary renal cell carcinoma risk criteria to a large prospective database. Clinical Oncology (Royal College of Radiologists), 32(1), e10-e15.
Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010). The genetic basis of kidney cancer: A metabolic disease. Nature Reviews Urology, 7(5), 277-285.
Lipworth, L., Morgans, A. K., Edwards, T. L., Barocas, D. A., Chang, S. S., Herrell, S. D., Penson, D. F., Resnick, M. J., Smith, J. A., & Clark, P. E. (2016). Renal cell cancer histological subtype distribution differs by race and sex. BJU International, 117(2), 260-265.
Maher, E. R. (2018). Hereditary renal cell carcinoma syndromes: Diagnosis, surveillance and management. World Journal of Urology, 36(12), 1891-1898.
Menko, F. H., Maher, E. R., Schmidt, L. S., Middelton, L. A., Aittomaki, K., Tomlinson, I., Richard, S., & Linehan, W. M. (2014). Hereditary leiomyomatosis and renal cell cancer (HLRCC): Renal cancer risk, surveillance and treatment. Familial Cancer, 13(4), 637-644.
Moch, H., Gasser, T., Amin, M. B., Torhorst, J., Sauter, G., & Mihatsch, M. J. (2000). Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A Swiss experience with 588 tumors. Cancer, 89(3), 604-614.
Motzer, R. J., Jonasch, E., Boyle, S., Carlo, M. I., Manley, B., Agarwal, N., Alva, A., Beckermann, K., Choueiri, T. K., Costello, B. A., Derweesh, I. H., Desai, A., George, S., Gore, J. L., Haas, N., Hancock, S. L., Kyriakopoulos, C., Lam, E. T., Lau, C., … Motter, A. D. (2020). NCCN guidelines insights: Kidney cancer, version 1.2021. Journal of the National Comprehensive Cancer Network, 18(9), 1160-1170.
Pilarski, R. (2009). Cowden syndrome: A critical review of the clinical literature. Journal of Genetic Counseling, 18(1), 13-27.
Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., Vocke, C., Brown, J. A., Jenkins, R., Richard, S., Bergerheim, U., Gerrard, B., Dean, M., Linehan, W. M., & Zbar, B. (1999). Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 18(14), 2343-2350.
Schmidt, L. S., & Linehan, W. M. (2016). Genetic predisposition to kidney cancer. Seminars in Oncology, 43(5), 566-574.
Schmidt, L. S., Nickerson, M. L., Angeloni, D., Glenn, G. M., Walther, M. M., Albert, P. S., Warren, M. B., Choyke, P. L., Torres-Cabala, C. A., Merino, M. J., Brunet, J., Berez, V., Borras, J., Sesia, G., Middelton, L., Phillips, J. L., Stolle, C., Zbar, B., Pautler, S. E., & Linehan, W. M. (2004). Early onset hereditary papillary renal carcinoma: Germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. Journal of Urology, 172(4 Pt 1), 1256-1261.
Schmidt, L. S., Nickerson, M. L., Warren, M. B., Glenn, G. M., Toro, J. R., Merino, M. J., Turner, M. L., Choyke, P. L., Sharma, N., Peterson, J., Morrison, P., Maher, E. R., Walther, M. M., Zbar, B., & Linehan, W. M. (2005). Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. American Journal of Human Genetics, 76(6), 1023-1033.
Shuch, B., Vourganti, S., Ricketts, C. J., Middleton, L., Peterson, J., Merino, M. J., Metwalli, A. R., Srinivasan, R., & Linehan, W. M. (2014). Defining early-onset kidney cancer: Implications for germline and somatic mutation testing and clinical management. Journal of Clinical Oncology, 32(5), 431-437.
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7-33.
Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(1), 7-34.
Silverberg, E., Boring, C. C., & Squires, T. S. (1990). Cancer statistics, 1990. CA: A Cancer Journal for Clinicians, 40(1), 9-26.
Truong, H., Hegarty, S. E., Gomella, L. G., Kelly, W. K., Trabulsi, E. J., Lallas, C. D., & Giri, V. N. (2017). Prevalence and characteristics of patients with suspected inherited renal cell cancer: Application of the ACMG/NSGC genetic referral guidelines to patient cohorts. Journal of Genetic Counseling, 26(3), 548-555.
U.S. Census Bureau. (2019). QuickFacts United States. Retrieved from https://www.census.gov/quickfacts/fact/table/US/RHI725219#RHI725219
Wilding, A., Ingham, S. L., Lalloo, F., Clancy, T., Huson, S. M., Moran, A., & Evans, D. G. (2012). Life expectancy in hereditary cancer predisposing diseases: An observational study. Journal of Medical Genetics, 49(4), 264-269.